Skip to main content
Clinical Trials/NCT05509660
NCT05509660
Completed
N/A

E-health Interventions for Common Mental Health Problems Among University Students in Sweden: Pilot Study of Transdiagnostic Internet-based Psychological Treatment

Uppsala University1 site in 1 country30 target enrollmentOctober 6, 2021

Overview

Phase
N/A
Intervention
Not specified
Conditions
Psychological Disorder
Sponsor
Uppsala University
Enrollment
30
Locations
1
Primary Endpoint
Treatment Credibility and expectancy Questionnaire (CEQ).
Status
Completed
Last Updated
last year

Overview

Brief Summary

This study comprises the pilot phase of a randomized controlled trial (NCT05085756) that will investigate the feasibility of a transdiagnostic CBT-based treatment for symptoms of depression and anxiety offered to Swedish university students. It will offer treatment to participants who have previously responded to a universal online mental health screen conducted in university setting (WHO-WMH-ICS survey).

The pilot study initially has a prospective single-group design where 30 college students with elevated depressive and/or anxiety symptoms are enrolled in 8 weeks of therapist-guided CBT treatment via the Internet. All participants included will receive treatment. Mid-treatment, participants that are judged to be at risk of treatment failure will be randomized (1:1 ratio) to either continued treatment with no change, or to receive added therapist-support intended to enhance outcome.

Pilot study outcomes include various aspects of feasibility: participant uptake, self-reported credibility and expectancy, adherence to treatment protocol and assessments, treatment satisfaction, potential adverse events, causes for premature termination of treatment, and procedures for providing additional therapist support to a subsample of participants after mid-treatment. Within-group effects for primary depression and anxiety measures will be quantified. A range of secondary measures are piloted for the subsequent randomized controlled trial. The assessment points for this study: Baseline; 8 points during treatment; post-treatment; 6-month follow-up; 12-month follow-up; 24 month follow up.

Note. This study is retrospectively registered; this registration was completed prior to any outcome data-analyses.

Registry
clinicaltrials.gov
Start Date
October 6, 2021
End Date
December 31, 2023
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Uppsala University
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • College/university student at institution of higher education in Sweden
  • Score 5-19 on the PHQ-9, and/or
  • Score ≥5 on the GAD-7
  • Completed baseline assessment

Exclusion Criteria

  • Pharmacotherapy for mental health issue during the past 3 weeks)
  • Concurrent psychological treatment during the past 3 weeks
  • Mild levels of mental ill-health (under cut-off for primary outcome measures)
  • Severe levels of mental ill-health
  • Suicidal ideation or plans

Outcomes

Primary Outcomes

Treatment Credibility and expectancy Questionnaire (CEQ).

Time Frame: Baseline

Credibility/expectancy. \[Feasibility and acceptability measure\]

Working Alliance Inventory - Short (WAI-S)

Time Frame: Mid-treatment (4 weeks)

The WAI-S is scale measuring the participants perceived working alliance with their therapist. \[Feasibility and acceptability measure\]

Treatment interest/uptake. Measured in terms of % participants who responded to the study invitation

Time Frame: Baseline

Interest for intervention \[Feasibility and acceptability measure\]

Treatment completion/adherence.

Time Frame: Post-treatment (8 weeks)

Adherence to the treatment protocol. Measured in terms of % completed modules and % of completed skills practices. \[Feasibility and acceptability measure\]

Assessment completion/adherence.

Time Frame: Post-treatment (8 weeks)

Adherence to assessment plan (% missing data). Measured in terms of % completed measures at post-treatment. \[Feasibility and acceptability measure\]

Added therapist support.

Time Frame: Mid-treatment (4 weeks)

Measured as % of participants who are randomized to receive additional therapist support for the remainder of the treatment period (weeks to 8).

Negative Effects Questionnaire (NEQ-20)

Time Frame: Mid-treatment (4 weeks)

NEQ-20 investigate negative effects of psychological treatment. Total range is 0-80, with higher values representing a worse outcome. \[Feasibility and acceptability measure\]

The Client Satisfaction Questionnaire-8 (CSQ-8)

Time Frame: Post-treatment (8 weeks)

Treatment satisfaction \[Feasibility and acceptability measure\]

Early treatment termination.

Time Frame: Post-treatment (8 weeks)

Measured as % of participants who decide to end treatment early. This includes reporting participants' reasons for early termination, where provided. \[Feasibility and acceptability measure\]

Secondary Outcomes

  • Generalized Anxiety Disorder scale (GAD-7)(Baseline, during treatment (weekly), post-treatment (8 weeks), follow-up at 6, 12, and 24 months)
  • Insomnia Severity Index (ISI)(Baseline; mid-treatment (4 weeks); post-treatment (8 weeks); follow-up at 6, 12, and 24 months)
  • Alcohol Use Disorders Identification Test - Consumption (AUDIT-C).(Baseline; post-treatment (8 weeks); follow-up at 6, 12, and 24 months)
  • World Health Organization Quality of Life Scale (WHOQOL-Bref).(Baseline; follow-up at 12 and 24 months)
  • Attitudes towards professional help (ATSPPHS)(Baseline; follow-up at 12 and 24 months)
  • Behavioral Activation for Depression Scale (BADS-9(Baseline; mid-treatment (week 4); post-treatment (8 weeks); follow-up at 6, 12, and 24 months)
  • Skills of Cognitive Therapy (SoCT)(Baseline; mid-treatment (4 weeks); post-treatment (8weeks); 24-month follow-up)
  • Difficulties in Emotion-Regulation Scale (DERS-16).(Baseline; post-treatment (8 weeks); follow-up at 6, 12, and 24 months)
  • Penn-State Worry Questionnaire (PSWQ)(Baseline; post-treatment (8 weeks); follow-up at 6, 12, and 24 months)
  • World Health Organization Well-being questionnaire (WHO-5).(Baseline; During treatment (weekly); post-treatment (8 weeks); follow-up at 6, 12, and 24 months)
  • Patient Health Questionnaire PHQ-9(Baseline, during treatment (weekly), post-treatment (8 weeks), follow-up at 6, 12, and 24 months)
  • Diagnostic and Statistical Manual of Mental Disorders Cross-Cutting Symptom Measure (DSM-5 CCSM)(Baseline; mid-treatment (week 4); post-treatment (8 weeks); follow-up at 6, 12, and 24 months)
  • Rosenberg Self-Esteem Scale (RESES)(Baseline; post-treatment (8 weeks); follow-up at 6, 12, and 24 months)
  • Connor-Davidson Resilience Scale.(Baseline; post-treatment (8 weeks); follow-up at 6, 12, and 24 months)
  • Big Five Inventory-10 (BFI-10)(Baseline; follow-up at 12 and 24 months)
  • Healthcare consumption and productivity loss in patients with a psychiatric disorder (TIC-P)(Baseline; follow-up at 6, 12, and 24 months)

Study Sites (1)

Loading locations...

Similar Trials